Efficacy of cross-line anti-programmed death 1/programmed cell death-ligand 1 antibody in the treatment of advanced nonsmall cell lung cancer: A retrospective study.

Xiang Zhao Yuan Cheng Cuiyan GuoLigong NieQi ZhangMeng ZhangKunyan SunGuangfa Wang

Published in: Health science reports (2024)

Cross-line ICIs cannot improve the prognosis and PFS2 of patients with NSCLC, but compared to discontinuing ICIs, OS may be prolonged. A few patients may benefit from prolonged ICIs therapy.

Keyphrases

end stage renal disease
ejection fraction
small cell lung cancer
single cell
cell therapy
stem cells
patient reported
replacement therapy
bone marrow
tyrosine kinase